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THE immunosuppressive agent FK 506 has been inves-tigated for its adverse effects on the liver, kidney, and 
the pancreas. I FK 506, however, has multiple biological 
effects which may be beneficial for the liver. For instance, 
pretreatment of rats with FK 506 has been shown to both 
protect the liver from ischemic injury2 and to ameliorate 
the hepatic injury associated with ischemia and reperfu-
sion in rats. 3 Other immunomodulators having different 
chemical structures have been shown to exhibit similar 
hepatoprotective effects with different types of hepatic 
injury.4-6 The aim of the present study was to assess the 
effect of FK 506 pretreatment on D-galactosamine-induced 
hepatitis. 
METHODS 
Male, adult Sprague-Dawley rats weighing 220 to 270 g were 
divided into four groups of six to twelve each. Groups I and 3 
were used as controls and were gavaged with water, while animals 
in groups 2 and 4 were given 0.3 mg/kg of FK 506 suspended in 
water orally. Twenty-four hours later, acute hepatic failure was 
induced by a single intraperitoneal injection of D-galactosamine 
hydrochloride dissolved in 0.9% NaCI at dose of 2 glkg for groups 
I and 2 and 2.5 g/kg for groups 3 and 4. All rats were observed for 
\0 days for survival. Blood was collected from the tail vein, and 
serum aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) levels were estimated at 24,48, and, when possible, 
72 hours after GA treatment. Seventy-two hours after the GA 
insult. 3 rats from groups 3 and 4 were anaesthesized, and the right 
lobe of the liver was removed and freeze-clamped with liquid 
nitrogen for A TP enzymatic analysis. The residual left hepatic 
lobe was utilized for histopathologic examination after the speci-
mens were fixed in 10% formalin, dehydrated, embedded in 
paraffin, cut at 5 /-Lm, and stained for histological examination with 
hematoxylin and eosin. The extent of the liver necrosis was 
estimated semiquantitatively. The number of frankly necrotic 
hepatocytes per 10 random high-power microscopic fields (Olym-
pus BH-2 microscope, 4oox) was counted. A portion of the frozen 
liver was ground in liquid nitrogen and 4% (wt/vol) precooled 
perchloric acid (I x 5 wtlvol) and then homogenized. The homog-
enized samples were centrifuged at 4°C at 3000 rpm for 10 
minutes. The supernatant was brought to pH 7 using 6 mollL 
K2C03 and respun at 4°C at 3000 rpm for 5 minutes. The resultant 
samples were analyzed for ATP by the Sigma kit (Sigma Chemical 
Co, St. Louis, Mo). All data are reported as mean ± SEM. The 
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Fig 1. (A) Plasma AST (U/L) levels in control rats (GA, 2 g/kg) or 
FK 506-treated ones (FK 506 + GA) as a function of time after GA; 
(8) plasma AL T (U/L) levels in control rats (GA, 2/kg) or FK 
506-treated ones (FK 506 + GAl as a function of time after GA. 
Points are means ± SEM. 
Transplantation Proceedings, Vol 23, No 6 (December), 1991: pp 2809-2811 2809 
2810 
4000 
---
Control 
A 
----+-- FK SaG-treated 
3000 
-E 
3 
u.. 2000 ~ 
I-
en 
< 
1000 
l~----r-~~-----r----~--~ 
o 10 20 30 40 50 
Time (hours) 
-
Control 4000 B 
--.- FK 506-treated 
3000 
-E 
3 
u.. 2000 en 
--
I-
~ 
< 
1000 
Time (hours) 
Fig 2. (A) Plasma AST (U/l) levels in control rats (GA, 2.5 g/kg) 
or FK 506-treated ones (FK 506 + GA) as a function of time after 
GA; (8) plasma Al T (U/l) levels in control rats (GA, 2.5 g/kg) or 
FK 506-treated ones (FK 506 + GA) as a function of time after GA. 
Points are means ± SEM. 
Student's t test was used for statistical analysis. P < .05 was 
considered significant. 
RESULTS 
FK 506 pretreatment increased the survival of groups 2 
and 4, where survival was 90% versus 100% and 50% 
versus 67% for groups 1, 2, 3, and 4, respectively. The 
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Fig 3. Hepatic ATP contents (jLmol/g of liver weight) in control 
rats (GA-treated) or FK 506-treated ones (FK 506 + GA). Values 
are means of 3 animals ± SEM. 
effect of FK 506 pretreatment on the GA (2 g/kg) induced 
increases in AST and AL T in groups 1 and 2 is given in Fig 
1 and 2, respectively. FK 506 pretreatment was associated 
with a significant reduction in the plasma levels of AST and 
ALT at all time intervals tested (P < .05). AST and ALT 
levels for groups 3 and 4 were estimated only after 24 and 
48 hours of GA administration, because rats were too ill at 
72 hours. Nevertheless, FK 506 pretreatment reduced 
both the AST and AL T levels at different time intervals as 
illustrated in Fig 3 and 4, respectively (P < .05). Moreover, 
the ATP levels within the liver of the FK 506-treated rats 
in group 4 was 3.4 ± 0.5 p,mollL per gram as compared to 
2.6 ± 0.2 p,mollL per gram for the controls in group 3 (P < 
.01). The number of frankly necrotic cells in the livers of 
the FK 506-treated rats of group 4 was significantly re-
duced (P < .01) versus that seen in the control livers of 
group 3 where they were 27 ± 7.6 versus 61 ± 8.2, 
respectively. 
DISCUSSION 
Recently, an interplay between pharmacologic immuno-
modulation and hepatic function has been shown to exist in 
several types of hepatic injury, which can be induced 
experimentally. In recent years, several reports demon-
strating a hepatotrophic effect of FK 506 when adminis-
tered before or immediately after a variety of hepatic 
injuries have been published.2•3 The study herein reported 
was directed to determine the effect of FK 506 pretreat-
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Fig 4. Number of hepatic parenchyma demonstrating necrosis in 
GA-treated rats (control, 2.5 g/kg) and FK 506-treated ones (FK + 
GA) 72 hours after GA administration. 
ment on yet another type of hepatic injury produced by 
o-galactosamine (GA). GA is a highly specific hepatotoxin 
that causes a dose-dependent depletion of uridine metab-
olites.7 A hepatoprotective effect of several immunomod-
ulators against chemically induced liver injury has been 
documented previouslyK~·UK9 The present data indicate a 
similar effect of FK 506 pretreatment in modulating the 
GA-induced hepatotoxicity at both dose levels used. He-
patoprotection was demonstrated by reduced plasma lev-
els of aminotransferases, increased survival, conservation 
of the energy status of the liver as evidenced by measure-
ment of hepatic ATP levels, and a reduced necrotic index 
as assessed histologically. 
2811 
A somewhat similar immunosuppressive agent, cyclo-
sporine, was also a hepatotrophic agent in rats or mice 
after partial hepatectomy, 1~1O and acts as chemopro-
tectant against the potent hepatotoxin microcystin, LR. \3 
It appears that FK 506 has a similar cytoprotective effect, 
as it is also protective against various kinds of hepatic 
insults ranging from surgical to chemical injury, and is 
shared by other immunomodulators, not all of which are 
immunosuppressive. The molecular mechanisms responsi-
ble for their cytoprotective action are not apparent and 
deserve further investigation. 
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